1. New approaches in the therapy of breast cancer — introduction

   • Robert B. Dickson
   • Marc E. Lippman

   Introduction Pages: 1 - 2

2. Recombinant immunotoxins

   • Ira Pastan
   • Lee H. Pai
   • David FitzGerald

   Immunotherapy Pages: 3 - 9

3. Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies

   • Roger R. Beerli
   • Winfried Wels
   • Nancy E. Hynes

   Immunotherapy Pages: 11 - 17

4. Preclinical testing of an anti-erbB-2 recombinant toxin

   • C. Richter King
   • Philip G. Kasprzyk
   • Nancy A. Turner

   Immunotherapy Pages: 19 - 25

5. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer

   • Jeffrey Schlom
   • Judy Kantor
   • J. Michael Hamilton

   Immunotherapy Pages: 27 - 39

6. Immunomodulation following chemotherapy

   • M. Obadina
   • U. Verma
   • A. Mazumder

   Immunotherapy Pages: 41 - 48

7. The multifunctional role of transforming growth factor (TGF)-ßs on mammary epithelial cell biology

   • Carlos L. Arteaga
   • Teresa C. Dugger
   • Stephen D. Hurd

   Tumor growth pathways and their inhibition Pages: 49 - 56

8. The significance ofheregulin in breast cancer tumor progression and drug resistance

   • R. Lupu
   • M. Cardillo
   • C. Tang

   Tumor growth pathways and their inhibition Pages: 57 - 66

9. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

   • A. E. Wakeling
   • A. J. Barker
   • J. R. Woodburn

   Tumor growth pathways and their inhibition Pages: 67 - 73

10. Farnesyltransferase inhibitors and anti-Ras therapy

    • Jackson B. Gibbs
    • Nancy E. Kohl
    • Allen Oliff

    Tumor growth pathways and their inhibition Pages: 75 - 83

11. The efficacy of 9-cis retinoic acid in experimental models of cancer

    • Marco M. Gottardis
    • William W. Lamph
    • Richard A. Heyman

    Tumor growth pathways and their inhibition Pages: 85 - 96

12. Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting

    • Adrian L. Harris
    • Huatang Zhang
    • Roy Bicknell

    Tumor-host interactions Pages: 97 - 108

13. Inhibition of fibroblast growth factors

    • Anton Wellstein
    • Frank Czubayko

    Tumor-host interactions Pages: 109 - 119

14. Anti-invasion drugs

    • R. B. Dickson
    • M. D. Johnson
    • J. Low

    Tumor-host interactions Pages: 121 - 132

15. Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors

    • Martin R. Schneider
    • Michael Schirner
    • Herrmann Graf

    Tumor-host interactions Pages: 133 - 141